The Parkinson-associated human P5B-ATPase ATP13A2 protects against the iron-induced cytotoxicity.
P-type ion pumps are membrane transporters that have been classified into five subfamilies termed P1-P5. The ion transported by the P5-ATPases is not known. Five genes named ATP13A1-ATP13A5 that belong to the P5-ATPase group are present in humans. Loss-of-function mutations in the ATP13A2 gene (PARK9, OMIM 610513) underlay a form of Parkinson's disease (PD) known as the Kufor-Rakeb syndrome (KRS), which belongs to the group of syndromes of neurodegeneration with brain iron accumulation (NBIA). Here we report that the cytotoxicity induced by iron exposure was two-fold reduced in CHO cells stably expressing the ATP13A2 recombinant protein (ATP13A2). Moreover, the iron content in ATP13A2 cells was lower than control cells stably expressing an inactive mutant of ATP13A2. ATP13A2 expression caused an enlargement of lysosomes and late endosomes. ATP13A2 cells exhibited a reduced iron-induced lysosome membrane permeabilization (LMP). These results suggest that ATP13A2 overexpression improves the lysosome membrane integrity and protects against the iron-induced cell damage.
From IQUIFIB-Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, Buenos Aires 1113, Argentina.
Débora E
DE
Rinaldi
From IQUIFIB-Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, Buenos Aires 1113, Argentina.
Gerardo R
GR
Corradi
From IQUIFIB-Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, Buenos Aires 1113, Argentina.
Lucía Martínez
LM
Cuesta
From IQUIFIB-Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, Buenos Aires 1113, Argentina. Electronic address: hpadamo@qb.ffyb.uba.ar.
Hugo P
HP
Adamo
From IQUIFIB-Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, Buenos Aires 1113, Argentina. Electronic address: ftpinto@qb.ffyb.uba.ar.
Felicitas
F
de Tezanos Pinto
D008841:Actin Cytoskeleton / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D016466:CHO Cells; D002470:Cell Survival / Q000187:drug effects; D002712:Chlorides / Q000633:toxicity*; D003412:Cricetulus; D004305:Dose-Response Relationship, Drug; D011992:Endosomes / Q000187:drug effects / Q000378:metabolism; D005290:Ferric Compounds / Q000633:toxicity*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007425:Intracellular Membranes / Q000187:drug effects / Q000378:metabolism; D008247:Lysosomes / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D009154:Mutation; D053141:Organelle Size / Q000187:drug effects; D010539:Permeability; D006180:Proton-Translocating ATPases / Q000235:genetics / Q000378:metabolism*; D014162:Transfection
C514983:ATP13A2 protein, human; D002712:Chlorides; D005290:Ferric Compounds; D006180:Proton-Translocating ATPases; C024555:ferric chloride
Iron; Lysosome membrane permeabilization; P(5B)-ATP13A2; P-type ATPase; Parkinson disease